Leadership

John Lunger is a senior biotech executive with more than a decade of leadership across drug development, manufacturing, corporate strategy, and M&A, most recently as Chief Patient Supply Officer and executive team member at Adaptimmune Therapeutics, where he led the CMC execution behind the 2024 FDA approval of TECELRA — the world’s first autologous engineered T-cell therapy for solid tumors — and helped drive more than $400 million in financings. Earlier roles at Merrimack Pharmaceuticals, VWR International, and Pfizer/Wyeth built deep expertise across commercial supply, strategic planning, and corporate development in international markets. A Distinguished Graduate of the U.S. Naval Academy and former U.S. Navy submarine officer, John holds an MBA from the University of Chicago Booth School of Business.

Arun Kejariwal is a biopharma operator with more than twenty-five years of experience across drug development, CMC, portfolio strategy, and commercial development, most recently at Spark Therapeutics, where he served as asset general manager for advanced therapy programs in CNS and rare disease, advancing programs from early concept through IND clearance, and later as Chief of Staff to the CEO through the company's strategic pivot and integration into Roche. Earlier roles at GSK, Pfizer, and Merck built deep expertise across portfolio and decision analysis, global commercial strategy, and asset valuation for licensing transactions. He has also worked in API manufacturing and compliance, and led the start-up of a multi-product biologics facility. Arun holds an MS in Chemical Engineering and an MBA.

Twenty-plus years as CFO across venture-backed and public biotechs. Concurrently CFO and advisor at Danforth Advisors and Chair of Kaizen Bioscience. B.S. Economics, Northeastern University.